PMC:7253235 / 14375-14693 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"496","span":{"begin":240,"end":251},"obj":"Chemical"},{"id":"502","span":{"begin":189,"end":202},"obj":"Disease"},{"id":"503","span":{"begin":257,"end":268},"obj":"Disease"}],"attributes":[{"id":"A496","pred":"tao:has_database_id","subj":"496","obj":"MESH:C524865"},{"id":"A502","pred":"tao:has_database_id","subj":"502","obj":"MESH:D006333"},{"id":"A503","pred":"tao:has_database_id","subj":"503","obj":"MESH:D009205"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Elevated cardiac biomarkers have also been associated with worse outcomes and or cardiac hemodynamic instability, including cytokine release syndrome from chimeric antigen therapy (CAR-T), heart failure from proteasome inhibitor use (i.e., carfilzomib), or myocarditis from immune checkpoint inhibitor therapy [38–41]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T24","span":{"begin":124,"end":132},"obj":"Body_part"},{"id":"T25","span":{"begin":189,"end":194},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma7088"}],"text":"Elevated cardiac biomarkers have also been associated with worse outcomes and or cardiac hemodynamic instability, including cytokine release syndrome from chimeric antigen therapy (CAR-T), heart failure from proteasome inhibitor use (i.e., carfilzomib), or myocarditis from immune checkpoint inhibitor therapy [38–41]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T18","span":{"begin":189,"end":194},"obj":"Body_part"}],"attributes":[{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"Elevated cardiac biomarkers have also been associated with worse outcomes and or cardiac hemodynamic instability, including cytokine release syndrome from chimeric antigen therapy (CAR-T), heart failure from proteasome inhibitor use (i.e., carfilzomib), or myocarditis from immune checkpoint inhibitor therapy [38–41]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T149","span":{"begin":189,"end":202},"obj":"Disease"},{"id":"T150","span":{"begin":257,"end":268},"obj":"Disease"}],"attributes":[{"id":"A149","pred":"mondo_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/MONDO_0005252"},{"id":"A150","pred":"mondo_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/MONDO_0004496"}],"text":"Elevated cardiac biomarkers have also been associated with worse outcomes and or cardiac hemodynamic instability, including cytokine release syndrome from chimeric antigen therapy (CAR-T), heart failure from proteasome inhibitor use (i.e., carfilzomib), or myocarditis from immune checkpoint inhibitor therapy [38–41]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T86","span":{"begin":181,"end":184},"obj":"http://purl.obolibrary.org/obo/CLO_0002199"},{"id":"T87","span":{"begin":189,"end":194},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T88","span":{"begin":189,"end":194},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T89","span":{"begin":189,"end":194},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T90","span":{"begin":189,"end":194},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T91","span":{"begin":314,"end":316},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"}],"text":"Elevated cardiac biomarkers have also been associated with worse outcomes and or cardiac hemodynamic instability, including cytokine release syndrome from chimeric antigen therapy (CAR-T), heart failure from proteasome inhibitor use (i.e., carfilzomib), or myocarditis from immune checkpoint inhibitor therapy [38–41]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T19","span":{"begin":164,"end":171},"obj":"Chemical"},{"id":"T20","span":{"begin":208,"end":228},"obj":"Chemical"},{"id":"T21","span":{"begin":219,"end":228},"obj":"Chemical"},{"id":"T22","span":{"begin":240,"end":251},"obj":"Chemical"},{"id":"T23","span":{"begin":292,"end":301},"obj":"Chemical"}],"attributes":[{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_52726"},{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_65347"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Elevated cardiac biomarkers have also been associated with worse outcomes and or cardiac hemodynamic instability, including cytokine release syndrome from chimeric antigen therapy (CAR-T), heart failure from proteasome inhibitor use (i.e., carfilzomib), or myocarditis from immune checkpoint inhibitor therapy [38–41]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T86","span":{"begin":124,"end":149},"obj":"Phenotype"},{"id":"T87","span":{"begin":189,"end":202},"obj":"Phenotype"},{"id":"T88","span":{"begin":257,"end":268},"obj":"Phenotype"}],"attributes":[{"id":"A86","pred":"hp_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A87","pred":"hp_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/HP_0001635"},{"id":"A88","pred":"hp_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/HP_0012819"}],"text":"Elevated cardiac biomarkers have also been associated with worse outcomes and or cardiac hemodynamic instability, including cytokine release syndrome from chimeric antigen therapy (CAR-T), heart failure from proteasome inhibitor use (i.e., carfilzomib), or myocarditis from immune checkpoint inhibitor therapy [38–41]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T88","span":{"begin":0,"end":318},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Elevated cardiac biomarkers have also been associated with worse outcomes and or cardiac hemodynamic instability, including cytokine release syndrome from chimeric antigen therapy (CAR-T), heart failure from proteasome inhibitor use (i.e., carfilzomib), or myocarditis from immune checkpoint inhibitor therapy [38–41]."}

{"project":"2_test","denotations":[{"id":"32462289-29567210-24380943","span":{"begin":311,"end":313},"obj":"29567210"},{"id":"32462289-29285538-24380943","span":{"begin":311,"end":313},"obj":"29285538"},{"id":"32462289-29536852-24380943","span":{"begin":311,"end":313},"obj":"29536852"}],"text":"Elevated cardiac biomarkers have also been associated with worse outcomes and or cardiac hemodynamic instability, including cytokine release syndrome from chimeric antigen therapy (CAR-T), heart failure from proteasome inhibitor use (i.e., carfilzomib), or myocarditis from immune checkpoint inhibitor therapy [38–41]."}